People · Operator
Named in public records as an officer, director or promoter · active 2008–2019 · Biotechnology, Other Energy, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juno Therapeutics, Inc. | — | Biotechnology | Growth/Late | $1.1B | $1.3B | 2014 |
| Constellation Pharmaceuticals Inc | — | Biotechnology | Series C | $286.4M | $2.7B | 2010 |
| Boston Power Inc | — | Other Energy | Series C | $178.4M | $239.5M | 2010 |
| Aveo Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $98.2M | $263.2M | 2009 |
| CymaBay Therapeutics, Inc. | — | Biotechnology | Series B | $90.6M | $12.9M | 2008 |
| Altea Therapeutics Corp | — | Biotechnology | Seed | $3.7M | $30.4M | 2010 |
Anthony Evnin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Anthony Evnin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Robert Nelsen | 1 | 22 |
| Bandel Carano | 1 | 17 |
| Russell Hirsch | 1 | 10 |
| David Goeddel | 1 | 10 |
| BRADLEY BOLZON | 1 | 10 |
| David Johnston | 1 | 8 |
| Robert Higgins | 1 | 7 |
| Richard Klausner | 1 | 7 |
| Nicholas Galakatos | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| Carl Goldfischer | 1 | 5 |
| Jesse I. Treu | 1 | 5 |
| Robert Zerbe | 1 | 5 |
| Douglas Cole | 1 | 5 |
| Jesse Treu | 1 | 4 |
| Anthony B. Evnin | 1 | 4 |
| Raju Kucherlapati | 1 | 4 |
| Alan Smith | 1 | 4 |
| Peter Svennilson | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.